Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance

Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown a high response rate and long progression-free survival in primary treatment of ALK-positive non-small-cell lung cancer (NSCLC). De novo resistance or refractory subtype is rare event. Herein, we identify the first case with serial next-generation sequencing (NGS) results that harboured a rare echinoderm microtubule associated protein like 4 gene (EML4) -ALK (breaking site at exon 19) fusion in a lung adenocarcinoma (LUAD) patient who acquired alectinib resistance rapidly (less than 3 months), followed by multi-drug resistance and short survival time.

Automated summary

After treatment with the first-line therapy drug alectinib for ALK-positive non-small-cell lung cancer, a patient rapidly acquired drug resistance, followed by multi-drug resistance and a short survival time.